Vasoactive intestinal peptide (28-amino-acid neuropeptide)
A naturally occurring signaling peptide with vasodilatory, anti-inflammatory, and immune-modulating actions.
| Class / type | Vasoactive intestinal peptide (28-amino-acid neuropeptide) |
|---|---|
| Category | Healing, Recovery & Immune |
| Status (Jul 2026) | Research use only |
VIP activates VPAC1/VPAC2 receptors, raising cyclic AMP to relax smooth muscle (vasodilation, bronchodilation), modulate immune/inflammatory signaling, and support pulmonary function.
Investigational for pulmonary hypertension, sarcoidosis, and inflammation; used off-label (typically compounded intranasal) in chronic inflammatory response syndrome (CIRS)/mold-illness protocols.
Anti-inflammatory and vasodilatory potential; CIRS proponents report symptom and quality-of-life improvements; active area of research.
Limited high-quality human evidence, especially for CIRS use; possible hypotension, flushing, diarrhea; very short half-life; nasal products are compounded and unregulated.
CIRS patient communities sometimes report notable benefit, but mainstream evidence is thin and results are anecdotal.
NOT FDA-approved; investigational, available only as a compounded/research preparation, not an approved therapy.